Company Overview of Nouscom AG
Nouscom AG develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses. The company is based in Basel, Switzerland.
41 61 201 18 31
Key Executives for Nouscom AG
Nouscom AG Key Developments
Similar Private Companies By Industry
|Acino International AG||Europe|
|AL-S Pharma AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
Recent Private Companies Transactions
October 26, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Nouscom AG, please visit dev.nouscom.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.